Nissay Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $19.1M | Buy |
30,636
+1,767
| +6% | +$1.2M | 0.08% | 167 |
|
|
2026
Q1 | $22.3M | Buy |
28,869
+843
| +3% | +$645K | 0.12% | 125 |
|
|
2025
Q4 | $21.6M | Buy |
28,026
+963
| +4% | +$654K | 0.11% | 124 |
|
|
2025
Q3 | $15.2M | Buy |
27,063
+107
| +0.4% | +$60.5K | 0.08% | 162 |
|
|
2025
Q2 | $14.2M | Buy |
26,956
+539
| +2% | +$301K | 0.08% | 169 |
|
|
2025
Q1 | $16.8M | Buy |
26,417
+2,292
| +10% | +$1.58M | 0.11% | 138 |
|
|
2024
Q4 | $17.2M | Buy |
24,125
+847
| +4% | +$711K | 0.1% | 136 |
|
|
2024
Q3 | $24.5M | Buy |
23,278
+1,921
| +9% | +$2.14M | 0.16% | 99 |
|
|
2024
Q2 | $22.4M | Buy |
21,357
+2,397
| +13% | +$2.32M | 0.15% | 91 |
|
|
2024
Q1 | $18.2M | Buy |
18,960
+4,295
| +29% | +$4.08M | 0.13% | 112 |
|
|
2023
Q4 | $12.9M | Buy |
14,665
+748
| +5% | +$616K | 0.1% | 132 |
|
|
2023
Q3 | $11.5M | Buy |
13,917
+882
| +7% | +$693K | 0.1% | 130 |
|
|
2023
Q2 | $9.37M | Sell |
13,035
-12
| -0.1% | -$9.25K | 0.08% | 146 |
|
|
2023
Q1 | $10.7M | Sell |
13,047
-416
| -3% | -$314K | 0.1% | 136 |
|
|
2022
Q4 | $9.71M | Sell |
13,463
-803
| -6% | -$593K | 0.09% | 141 |
|
|
2022
Q3 | $9.83M | Buy |
14,266
+560
| +4% | +$352K | 0.1% | 124 |
|
|
2022
Q2 | $8.1M | Buy |
13,706
+560
| +4% | +$364K | 0.08% | 144 |
|
|
2022
Q1 | $9.18M | Buy |
13,146
+274
| +2% | +$173K | 0.08% | 148 |
|
|
2021
Q4 | $8.13M | Buy |
12,872
+431
| +3% | +$265K | 0.06% | 184 |
|
|
2021
Q3 | $7.53M | Sell |
12,441
-366
| -3% | -$227K | 0.06% | 176 |
|
|
2021
Q2 | $7.15M | Sell |
12,807
-420
| -3% | -$213K | 0.06% | 183 |
|
|
2021
Q1 | $6.26M | Sell |
13,227
-317
| -2% | -$154K | 0.06% | 185 |
|
|
2020
Q4 | $6.54M | Buy |
13,544
+610
| +5% | +$329K | 0.1% | 168 |
|
|
2020
Q3 | $7.24M | Sell |
12,934
-486
| -4% | -$295K | 0.12% | 137 |
|
|
2020
Q2 | $8.37M | Sell |
13,420
-10,373
| -44% | -$5.89M | 0.16% | 134 |
|
|
2020
Q1 | $11.6M | Sell |
23,793
-14,913
| -39% | -$6.15M | 0.3% | 87 |
|
|
2019
Q4 | $14.5M | Sell |
38,706
-2,424
| -6% | -$816K | 0.32% | 82 |
|
|
2019
Q3 | $11.4M | Buy |
41,130
+6,347
| +18% | +$1.88M | 0.28% | 92 |
|
|
2019
Q2 | $10.9M | Sell |
34,783
-1,229
| -3% | -$409K | 0.28% | 91 |
|
|
2019
Q1 | $14.8M | Sell |
36,012
-998
| -3% | -$411K | 0.39% | 63 |
|
|
2018
Q4 | $13.8M | Buy |
37,010
+386
| +1% | +$141K | 0.42% | 56 |
|
|
2018
Q3 | $14.8M | Buy |
36,624
+2,436
| +7% | +$927K | 0.4% | 57 |
|
|
2018
Q2 | $11.8M | Buy |
34,188
+5,957
| +21% | +$1.86M | 0.35% | 68 |
|
|
2018
Q1 | $9.72M | Buy |
28,231
+4,856
| +21% | +$1.69M | 0.3% | 78 |
|
|
2017
Q4 | $8.79M | Buy |
+23,375
| New | +$9.47M | 0.27% | 91 |
|
Other funds holding REGN
Nissay Asset Management's REGN Position: Q2 2026 in Review
Nissay Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 6.1% in Q2 2026, buying an estimated $1.2M and bringing the position to 30,636 shares worth $19.1M. The position accounts for 0.08% of the portfolio, ranked #167.
Nissay Asset Management first reported a position in REGN in Q4 2017 and has held it in 35 quarters since. The position peaked at $24.5M in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Nissay Asset Management held 30,636 shares of Regeneron Pharmaceuticals worth $19.1M as of Q2 2026.
- Nissay Asset Management bought 1,767 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.2M.
- Regeneron Pharmaceuticals made up 0.08% of Nissay Asset Management's portfolio in Q2 2026, its #167 holding.
- Nissay Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- Nissay Asset Management's Regeneron Pharmaceuticals position peaked at $24.5M in Q3 2024.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Nissay Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.